Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2004

View Archived Issues

Thiazolidinediones reduce cardiac events in diabetic heart transplant patients

Specific cannabinoid receptor agonist may prevent tissue damage in retina

Preliminary evidence for the benefits of aromatase inhibitors in epilepsy

Levetiracetam reported to reduce the frequency of transformed migraine

Neuroprotection from focal ischemic injury by TACE inhibitor DPH-067517

Fludarabine reported effective in controlling break through multiple sclerosis

Modafinil and interferon beta improve cognitive impairment in relapsing-remitting MS

BAL-5788 effective against antibiotic-resistant strains of pneumonia

Statins and fibrates delay cognition decline in AD

Clinical benefits of tacrolimus in patients with myasthenia gravis

Interim results from phase II trial of Metastat

New approval for Enbrel in psoriasis

MAGNET liver cancer trial stopped early

Zelnorm labeling updated with new risk information

UCB-44212 Keppra analogue enters phase I

Phase I trial evaluates intranasal PTH1-34

Preliminary results from Oralin clinical study

Avanir completes initial phase I study of AVP-13358

Panacea collaborates with M.D. Anderson Cancer Center on HAAH program

ThPTH successfully tested in first-in-man study

AMDL seeks partner for Combination Immunogene Therapy

Peptech and Agenix to merge

Australian Pentrys phase II trial commences

Orphan drug status for PI-88 for malignant melanoma

M-55529: A novel, selective factor Xa inhibitor from Mochida

Two series of antimycobacterial agents prepared and tested at Lupin

Merck describes new glucocorticoid receptor modulators and their use

Novel estrogen receptor modulators under study at Merck

New urotensin II antagonists covered by Actelion patent

New adenosine A1 agonists, their preparation and use, reported by GSK team

New orexin antagonists for obesity and sleep disorders claimed by GSK